var data={"title":"Halothane hepatitis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Halothane hepatitis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/contributors\" class=\"contributor contributor_credentials\">Anne M Larson, MD, FACP, FAASLD, AGAF</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/contributors\" class=\"contributor contributor_credentials\">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/contributors\" class=\"contributor contributor_credentials\">Kristen M Robson, MD, MBA, FACG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Inhaled anesthetics were first used in the mid-1800s with the discovery of diethyl ether [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Prior to the 1950s, ether and chloroform were used exclusively. Halothane, a halogenated anesthetic, was first synthesized in 1951 [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/3\" class=\"abstract_t\">3</a>]. It was reported in 1956 as an anesthetic based on animal studies [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/4\" class=\"abstract_t\">4</a>]. It was first introduced into use on January 20, 1956, and rapidly replaced both ether and chloroform as the surgical anesthetic of choice [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/3,5-8\" class=\"abstract_t\">3,5-8</a>].</p><p>Isolated case reports of severe hepatitis were soon reported [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/9-13\" class=\"abstract_t\">9-13</a>]. The Committee on Anesthesia of the National Academy of Sciences-National Research Council formed a group in 1961 to investigate the association of halothane with hepatotoxicity [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/3,14\" class=\"abstract_t\">3,14</a>]. In 1969, the report was published. A review of 250,000 cases of halothane use revealed an incidence of fatal hepatic necrosis of approximately 1 in 35,000 exposures [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/15\" class=\"abstract_t\">15</a>]. This review, however, was unable to establish a direct correlation between halothane use and liver damage [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/14\" class=\"abstract_t\">14</a>]. A similar large-scale review in the United Kingdom showed nearly identical results [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/16\" class=\"abstract_t\">16</a>]. Halothane became the most common cause of idiosyncratic drug-induced liver failure by the 1970s [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/17\" class=\"abstract_t\">17</a>]. Since then, less and less hepatotoxic alternatives have been serially introduced: enflurane (1972), <a href=\"topic.htm?path=isoflurane-drug-information\" class=\"drug drug_general\">isoflurane</a> (1981), <a href=\"topic.htm?path=desflurane-drug-information\" class=\"drug drug_general\">desflurane</a> (1993) and <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> (1995) [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/18,19\" class=\"abstract_t\">18,19</a>]. However, reports of hepatotoxicity with these medications also exist [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/20-33\" class=\"abstract_t\">20-33</a>].</p><p>Initially, toxicity to halothane was not reported in children. Subsequent reports, however, demonstrated that the incidence of halothane-associated hepatitis in children is between 1 in 82,000 and 1 in 200,000 [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/34-39\" class=\"abstract_t\">34-39</a>]. Halothane use in children has been largely replaced by <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/40\" class=\"abstract_t\">40</a>]. The reason for the lower incidence of halothane-associated hepatitis observed in children is unclear [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/41,42\" class=\"abstract_t\">41,42</a>]. </p><p>Concern about hepatotoxicity has virtually eliminated the use of halothane in adults in the United States and Europe. Worldwide, however, halothane is possibly the most commonly used inhalational anesthetic, particularly in the Middle East and Africa [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/3,43,44\" class=\"abstract_t\">3,43,44</a>]. This is predominantly due to its low cost compared to other anesthetics. Reports of hepatotoxicity continue to be published [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/45-48\" class=\"abstract_t\">45-48</a>].</p><p>Approximately 60 to 80 percent of the inhaled anesthetics are eliminated unchanged via the respiratory system [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/49\" class=\"abstract_t\">49</a>]. However, their lipophilic nature allows some systemic absorption. This portion of anesthetic must then be detoxified, a process occurring predominantly within the liver. The nontoxic product is then excreted in the urine.</p><p>This topic will review hepatotoxicity related to halothane. Hepatotoxicity related to other medications, herbs, and dietary supplements is discussed separately. (See <a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">&quot;Drug-induced liver injury&quot;</a> and <a href=\"topic.htm?path=hepatotoxicity-due-to-herbal-medications-and-dietary-supplements\" class=\"medical medical_review\">&quot;Hepatotoxicity due to herbal medications and dietary supplements&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Halothane is associated with two clinical patterns of liver injury: hepatotoxicity and hepatitis [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/47,50-55\" class=\"abstract_t\">47,50-55</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Halothane hepatotoxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatotoxicity can occur with or without prior halothane exposure. Postoperative elevation in serum aminotransferases has been observed in 20 to 30 percent of patients [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/15,16,50,56-58\" class=\"abstract_t\">15,16,50,56-58</a>]. Most patients are asymptomatic, although a subset develops symptoms of mild clinical hepatitis characterized by nausea, lethargy, and fever. The aminotransferases remain elevated for one to two weeks following exposure and resolve without treatment [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/57\" class=\"abstract_t\">57</a>]. This reaction is generally considered a non-immune phenomenon [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/59\" class=\"abstract_t\">59</a>]. Recovery is the rule.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Halothane hepatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A more rare and unpredictable occurrence is an acute severe hepatitis, &quot;halothane hepatitis,&quot; with potential development of hepatic necrosis and acute liver failure, which is often fatal [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/52,60,61\" class=\"abstract_t\">52,60,61</a>]. The incidence is 1 in 6000 to 1 in 15,000 following a single exposure to the anesthetic, and increases to approximately 1 in 1000 following multiple exposures, particularly if they occur within 28 days of prior exposure [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/14,16,61-65\" class=\"abstract_t\">14,16,61-65</a>]. Other risk factors for severe hepatotoxicity may include short intervals between exposures, female sex (2:1), age greater than 40 years (80 percent of cases), obesity, underlying liver dysfunction, and a genetic predisposition to hepatitis [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/15,16,20,63,66-70\" class=\"abstract_t\">15,16,20,63,66-70</a>]. In addition, injury may be more severe if CYP2E1 has been induced by other medications (ie, <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>, alcohol, or <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>) [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/58,67,71\" class=\"abstract_t\">58,67,71</a>].</p><p>Symptoms generally develop approximately two days to three weeks after exposure. Approximately 75 percent of patients present with a fever and may complain of anorexia, nausea, myalgias, arthralgias, and rash [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/72,73\" class=\"abstract_t\">72,73</a>]. Eosinophilia occurs in approximately 40 percent of cases, suggesting that toxicity is immunoallergic [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/74,75\" class=\"abstract_t\">74,75</a>]. Tender hepatomegaly and jaundice are common. Some patients present with acute liver failure, markedly elevated serum aminotransferases and prothrombin time, and possibly hepatic encephalopathy [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/52\" class=\"abstract_t\">52</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">MECHANISM OF HEPATOTOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatotoxic drugs result in a variety of histopathologic patterns of injury, including those characterized predominantly by damage to hepatocytes, bile ducts, or a combination of the two. Halothane leads predominantly to hepatocellular damage. (See <a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">&quot;Drug-induced liver injury&quot;</a>.)</p><p>Halothane is metabolized predominantly by the cytochrome P450 system. While the precise mechanism of hepatotoxicity remains unknown, most hypothesize that toxicity results from halothane's hepatic biotransformation to reactive intermediates [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53,62,76-81\" class=\"abstract_t\">53,62,76-81</a>]. Of the commonly used volatile anesthetics, halothane is the most extensively metabolized (20 to 30 percent), compared with the newer anesthetics (2 percent for enflurane, 1 percent for <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a>, &le;0.2 percent for <a href=\"topic.htm?path=isoflurane-drug-information\" class=\"drug drug_general\">isoflurane</a> and <a href=\"topic.htm?path=desflurane-drug-information\" class=\"drug drug_general\">desflurane</a>) [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/59\" class=\"abstract_t\">59</a>]. This may explain halothane's propensity to hepatotoxicity [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/62,82,83\" class=\"abstract_t\">62,82,83</a>]. Both oxidation and reduction occur concurrently, depending upon the relative hypoxia within a particular region of the liver [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53\" class=\"abstract_t\">53</a>]. Conditions of low oxygen tension (hypoxia) favor reductive metabolism via CYP2A6 and CYP3A4, while conditions of normal oxygen tension (normoxia) favor oxidative metabolism via CYP2E1 and CYP2A6 [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53,76,77,84-86\" class=\"abstract_t\">53,76,77,84-86</a>]. The oxidative pathway predominates under physiologic conditions; less than 1 percent is metabolized via the reductive pathway [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/76,85,87\" class=\"abstract_t\">76,85,87</a>]. Additionally, there is evidence that the immune system participates in development and propagation of halothane hepatitis.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Halothane hepatotoxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatic injury leading to severe halothane hepatotoxicity is believed to be secondary to intrahepatic anaerobic halothane reduction (1 to 3 percent of the total anesthetic dose) via the reductive pathway. Halothane decreases both portal venous and hepatic arterial blood flow in proportion to the degree of anesthesia, leading to an alteration in hepatic oxygen metabolism and relative hepatic hypoxia [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/87-89\" class=\"abstract_t\">87-89</a>]. The risk may be increased in patients with chronic liver disease, particularly if cirrhosis is present [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/49\" class=\"abstract_t\">49</a>]. Although hypoxia alone does not explain halothane hepatotoxicity, it may predispose the liver to halothane-induced damage [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/90,91\" class=\"abstract_t\">90,91</a>].</p><p>Reductive pathways produce the free radical intermediate 2-chloro-1,1,1-trifluroethyl (CF3CHCl). This free radical may form the stable metabolites of chlorotrifluoroethane (CTE) or chlorodifluoroethene (CDE), which are then excreted [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53\" class=\"abstract_t\">53</a>]. These metabolites can be found in the exhaled breath [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/92\" class=\"abstract_t\">92</a>]. However, the free radical can also covalently bind with cellular proteins and lipids, which may lead to lipid peroxidation, inactivation and destruction of CYP450 with resultant serum aminotransferase elevation [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53,78,86,93-98\" class=\"abstract_t\">53,78,86,93-98</a>]. This is likely the mechanism responsible for the milder form of halothane hepatotoxicity [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/96,99\" class=\"abstract_t\">96,99</a>]. However, it is generally accepted that a significant free radical-mediated toxic mechanism is unlikely to take place under the usual physiologic conditions [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/100\" class=\"abstract_t\">100</a>]. Biotransformation appears necessary for halothane hepatotoxicity [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Halothane hepatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Halothane hepatitis is widely believed to result from an immunologically-based hypersensitivity reaction initiated by oxidative metabolism [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53,101,102\" class=\"abstract_t\">53,101,102</a>]. Halothane hepatitis is often associated with the clinical features of an immunologic disorder, including rash, arthralgias, eosinophilia, and increased levels of circulating immune complexes [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/73,75,84,103\" class=\"abstract_t\">73,75,84,103</a>].</p><p>The halothane oxidative pathway is catalyzed predominantly by CYP2E1 and to a lesser extent by CYP2A6 (at high halothane concentrations). This pathway accounts for the majority of the drug's metabolism. Oxidation leads to a reactive acyl chloride (CF3COCl) that reacts with lysine to produce a highly reactive metabolite, trifluoroacetyl chloride (TFA) [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53,76,77,85,104-107\" class=\"abstract_t\">53,76,77,85,104-107</a>]. Subsequent hydrolysis of TFA yields trifluoroacetic acid, which is nontoxic and is excreted in the urine [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/62,85\" class=\"abstract_t\">62,85</a>]. However, in certain cases, TFA may also bind covalently to hepatocyte macromolecules and phospholipids, producing trifluoroacetylated-protein adducts (TFA-protein adducts) [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53,105,106,108-110\" class=\"abstract_t\">53,105,106,108-110</a>]. Covalent binding to liver proteins may be the preliminary step in the development of acute halothane hepatitis [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/99,111\" class=\"abstract_t\">99,111</a>]. The TFA-protein adducts are immunogenic to the adaptive immune system and act as sensitizing neoantigens, evoking an immune-mediated response and the development of antibodies [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/112,113\" class=\"abstract_t\">112,113</a>]. With subsequent exposures, these antibodies can again mediate the immune injury and lead to more severe hepatotoxicity, with an incidence of up to 1 in 1,000 [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/49,53,62,84,104,114\" class=\"abstract_t\">49,53,62,84,104,114</a>].</p><p>Circulating immunoglobulin G against hepatocytes and TFA-protein adducts can be detected in the serum and liver of patients with halothane hepatitis [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/73,74,105,115-124\" class=\"abstract_t\">73,74,105,115-124</a>]. The antibodies recognize either TFA-adducts or native proteins that mimic TFA-adducts [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/125,126\" class=\"abstract_t\">125,126</a>]. TFA-adducts may also be located in the Kupffer cells, which may then function as TFA-protein antigen-presenting cells [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/82,127,128\" class=\"abstract_t\">82,127,128</a>]. Neoantigens, including CYP2E1, may be expressed on the hepatocyte surface and are also recognized by these antibodies [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/84,120,123,129\" class=\"abstract_t\">84,120,123,129</a>]. TFA-products have also been identified in the kidney [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/130\" class=\"abstract_t\">130</a>], heart [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/131\" class=\"abstract_t\">131</a>], testes [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/129\" class=\"abstract_t\">129</a>], and lungs [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/132\" class=\"abstract_t\">132</a>], although in smaller amounts than seen in liver, and they are of unknown clinical significance. Eosinophils and micro-ribonucleic acids (microRNAs) may also play a significant role in hepatic injury [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/133-135\" class=\"abstract_t\">133-135</a>]. </p><p>As noted above, the severe hepatitis induced by halothane results predominantly from an immune-mediated response directed against the hepatocytes [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/87\" class=\"abstract_t\">87</a>]. However, while all exposures to halothane produce a variety of TFA-protein adducts [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/62,108\" class=\"abstract_t\">62,108</a>], halothane hepatitis remains rare. In addition, not all cases support a purely adaptive immune mechanism. This suggests that an additional predisposition to hepatocellular damage must be present. A genetic susceptibility has been reported [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/121,136,137\" class=\"abstract_t\">121,136,137</a>]. Patients who experience halothane hepatitis have an increased frequency of HLA-DR2, and halothane hepatitis can be seen among closely related family members [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/122,138\" class=\"abstract_t\">122,138</a>]. However, identification of genetic susceptibility factors remains to be determined.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of halothane hepatitis is made clinically, based on history and physical findings in the setting of postoperative hepatitis or jaundice following halothane use. However, the differential diagnosis of postoperative jaundice is broad and includes surgical complications (particularly in bile-duct surgery), perioperative hypotension with hypoxic hepatic injury, sepsis, infections, other drug hepatotoxicity, hemolysis after blood transfusion, and viral hepatitis. Halothane hepatitis remains a diagnosis of exclusion. Features that suggest halothane hepatitis include high fever within 3 to 14 days following exposure, recent exposure to the anesthetic, eosinophilic leukocytosis (seen in 20 percent), and a more severe course.</p><p>Liver biopsy is usually not necessary for diagnosis. When obtained, the histologic appearance is often indistinguishable from viral hepatitis. Patients with severe disease develop centrilobular hepatic necrosis with mild cholestasis [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/139\" class=\"abstract_t\">139</a>]. Fatty degeneration and vacuolation may be seen. Occasionally, an increase in eosinophils may be seen in the inflammatory infiltrate, and rarely, granulomata may be present.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of both halothane hepatotoxicity and halothane hepatitis is supportive [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/52\" class=\"abstract_t\">52</a>]. Glucocorticoids are of no proven value and there are little to no data to support their use. An exception is a single case report in which resolution was observed after initiation of glucocorticoids [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/140\" class=\"abstract_t\">140</a>]. Another case report described resolution of jaundice after treatment with methionine [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/141\" class=\"abstract_t\">141</a>]. In the setting of acute liver failure, the case fatality rate is approximately 50 percent but can be as high as 80 percent in those who develop hepatic encephalopathy [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/52,142\" class=\"abstract_t\">52,142</a>]. Severe, progressive cases may require emergent liver transplantation. (See <a href=\"topic.htm?path=acute-liver-failure-in-adults-management-and-prognosis\" class=\"medical medical_review\">&quot;Acute liver failure in adults: Management and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most effective preventive tool is to avoid the use of halothane in adults. This is particularly true in patients with prior exposure to the drug since the overall incidence of hepatic necrosis rises to as high as 1:1000 after multiple exposures [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/14\" class=\"abstract_t\">14</a>]. Guidelines have been proposed to minimize toxicity [<a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/71\" class=\"abstract_t\">71</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Halothane is associated with two patterns of clinical hepatotoxicity. Halothane hepatotoxicity is associated with an increase in serum aminotransferase either without symptoms or with mild, self-limited symptoms, while halothane hepatitis is associated with severe hepatitis or acute liver failure. (See <a href=\"#H2\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of halothane hepatitis is made clinically, based on history and physical findings in the setting of postoperative hepatitis or jaundice following halothane use. However, the differential diagnosis of postoperative jaundice is broad and includes surgical complications (particularly in bile-duct surgery), perioperative hypotension with hypoxic hepatic injury, sepsis, infections, other drug hepatotoxicity, hemolysis after blood transfusion, and viral hepatitis. (See <a href=\"#H8\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients who have developed halothane hepatitis, we suggest supportive treatment (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H9\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most effective preventive tool is to avoid the use of halothane, particularly in patients with prior exposure to the drug. (See <a href=\"#H10\" class=\"local\">'Prevention'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/1\" class=\"nounderline abstract_t\">Eger EI 2nd. Current and future perspectives on inhaled anesthetics. Pharmacotherapy 1998; 18:895.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/2\" class=\"nounderline abstract_t\">Eger EI 2nd. Characteristics of anesthetic agents used for induction and maintenance of general anesthesia. Am J Health Syst Pharm 2004; 61 Suppl 4:S3.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/3\" class=\"nounderline abstract_t\">Huang L, Sang CN, Desai MS. Beyond Ether and Chloroform-A Major Breakthrough With Halothane. J Anesth Hist 2017; 3:87.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/4\" class=\"nounderline abstract_t\">RAVENTOS J. The action of fluothane; a new volatile anaesthetic. Br J Pharmacol Chemother 1956; 11:394.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/5\" class=\"nounderline abstract_t\">JOHNSTONE M. The human cardiovascular response to fluothane anaesthesia. Br J Anaesth 1956; 28:392.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/6\" class=\"nounderline abstract_t\">SUCKLING CW. Some chemical and physical factors in the development of fluothane. Br J Anaesth 1957; 29:466.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/7\" class=\"nounderline abstract_t\">JOHNSTONE M. Halothane: the first five years. Anesthesiology 1961; 22:591.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/8\" class=\"nounderline abstract_t\">BRYCE-SMITH R, O'BRIEN HD. Fluothane: a non-explosive volatile anesthetic agent. Br Med J 1956; 2:969.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/9\" class=\"nounderline abstract_t\">Virtue RW, Payne KW. Postoperative death after Fluothane. Anesthesiology 1958; 19:562.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/10\" class=\"nounderline abstract_t\">LINDENBAUM J, LEIFER E. Hepatic necrosis associated with halothane anesthesia. N Engl J Med 1963; 268:525.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/11\" class=\"nounderline abstract_t\">BRODY GL, SWEET RB. Halothane anesthesia as a possible cause of massive hepatic necrosis. Anesthesiology 1963; 24:29.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/12\" class=\"nounderline abstract_t\">HEIDENBERG WJ, TORIO I. Additional case of halothane hepatitis. N Engl J Med 1963; 268:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/13\" class=\"nounderline abstract_t\">KERBEL NC, HILLIARD IM. HALOTHANE HEPATOTOXICITY. Can Med Assoc J 1963; 89:944.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/14\" class=\"nounderline abstract_t\">Summary of the national Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis. JAMA 1966; 197:775.</a></li><li class=\"breakAll\">Bunker JP, Forrest WH, Mosteller F, et al (Eds).. National Halothane Study. A study of the possible association between halothane anesthesia and postoperative hepatic necrosis. U.S. Government Printing Office, Washington, DC 1969.</li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/16\" class=\"nounderline abstract_t\">Walton B, Simpson BR, Strunin L, et al. Unexplained hepatitis following halothane. Br Med J 1976; 1:1171.</a></li><li class=\"breakAll\">https://livertox.nih.gov/Halogenatedanesthetics.htm (Accessed on September 06, 2017).</li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/18\" class=\"nounderline abstract_t\">Black GW, Clarke RS. Recently introduced anesthetic drugs. Int Anesthesiol Clin 1971; 9:171.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/19\" class=\"nounderline abstract_t\">Stevens WC. New halogenated anesthetics: enflurane and isoflurane. Calif Med 1972; 117:47.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/20\" class=\"nounderline abstract_t\">Stachnik J. Inhaled anesthetic agents. Am J Health Syst Pharm 2006; 63:623.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/21\" class=\"nounderline abstract_t\">Ihtiyar E, Algin C, Haciolu A, Isiksoy S. Fatal isoflurane hepatotoxicity without re-exposure. Indian J Gastroenterol 2006; 25:41.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/22\" class=\"nounderline abstract_t\">White LB, DeTarnowsky GO, Mir JA, Layden TJ. Hepatotoxicity following enflurane anesthesia. Dig Dis Sci 1981; 26:466.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/23\" class=\"nounderline abstract_t\">Paull JD, Fortune DW. Hepatotoxicity and death following two enflurane anaesthetics. Anaesthesia 1987; 42:1191.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/24\" class=\"nounderline abstract_t\">Weitz J, Kienle P, B&ouml;hrer H, et al. Fatal hepatic necrosis after isoflurane anaesthesia. Anaesthesia 1997; 52:892.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/25\" class=\"nounderline abstract_t\">Martin JL, Plevak DJ, Flannery KD, et al. Hepatotoxicity after desflurane anesthesia. Anesthesiology 1995; 83:1125.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/26\" class=\"nounderline abstract_t\">Tung D, Yoshida EM, Wang CS, Steinbrecher UP. Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anaesth 2005; 52:133.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/27\" class=\"nounderline abstract_t\">Singhal S, Gray T, Guzman G, et al. Sevoflurane hepatotoxicity: a case report of sevoflurane hepatic necrosis and review of the literature. Am J Ther 2010; 17:219.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/28\" class=\"nounderline abstract_t\">Turillazzi E, D'Errico S, Neri M, et al. A fatal case of fulminant hepatic necrosis following sevoflurane anesthesia. Toxicol Pathol 2007; 35:840.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/29\" class=\"nounderline abstract_t\">Christ DD, Kenna JG, Kammerer W, et al. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988; 69:833.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/30\" class=\"nounderline abstract_t\">Carrigan TW, Straughen WJ. A report of hepatic necrosis and death following isoflurane anesthesia. Anesthesiology 1987; 67:581.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/31\" class=\"nounderline abstract_t\">Chase RE, Holaday DA, Fiserova-Bergerova V, et al. The biotransformation of ethrane in man. Anesthesiology 1971; 35:262.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/32\" class=\"nounderline abstract_t\">Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 1983; 98:984.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/33\" class=\"nounderline abstract_t\">Sinha A, Clatch RJ, Stuck G, et al. Isoflurane hepatotoxicity: a case report and review of the literature. Am J Gastroenterol 1996; 91:2406.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/34\" class=\"nounderline abstract_t\">Carney FM, Van Dyke RA. Halothane hepatitis: a critical review. Anesth Analg 1972; 51:135.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/35\" class=\"nounderline abstract_t\">Warner LO, Beach TP, Garvin JP, Warner EJ. Halothane and children: the first quarter century. Anesth Analg 1984; 63:838.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/36\" class=\"nounderline abstract_t\">Munro HM, Snider SJ, Magee JC. Halothane-associated hepatitis in a 6-year-old boy: evidence for native liver regeneration following failed treatment with auxiliary liver transplantation. Anesthesiology 1998; 89:524.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/37\" class=\"nounderline abstract_t\">Lewis RB, Blair M. Halothane hepatitis in a young child. Br J Anaesth 1982; 54:349.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/38\" class=\"nounderline abstract_t\">Kenna JG, Neuberger J, Mieli-Vergani G, et al. Halothane hepatitis in children. Br Med J (Clin Res Ed) 1987; 294:1209.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/39\" class=\"nounderline abstract_t\">Vorrakitpokatorn P, Limsakul A. Drug-induced hyperthermia and rhabdomyolysis during the perioperative period: report of three patients. J Med Assoc Thai 2002; 85 Suppl 3:S884.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/40\" class=\"nounderline abstract_t\">Goa KL, Noble S, Spencer CM. Sevoflurane in paediatric anaesthesia: a review. Paediatr Drugs 1999; 1:127.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/41\" class=\"nounderline abstract_t\">Wark H, Earl J, Chau DD, Overton J. Halothane metabolism in children. Br J Anaesth 1990; 64:474.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/42\" class=\"nounderline abstract_t\">Gallagher TM, Black GW. Uptake of volatile anaesthetics in children. Anaesthesia 1985; 40:1073.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/43\" class=\"nounderline abstract_t\">Wiklund RA, Rosenbaum SH. Anesthesiology. First of two parts. N Engl J Med 1997; 337:1132.</a></li><li class=\"breakAll\">http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1 (Accessed on September 06, 2017).</li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/45\" class=\"nounderline abstract_t\">Qureshi MA, Saeed F, Hussain T. Halothane induced fulminant hepatic failure. J Coll Physicians Surg Pak 2007; 17:103.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/46\" class=\"nounderline abstract_t\">Kumar GP, Bhat VJ, Sowdi V. Fulminant hepatic failure following halothane anaesthesia. J Clin Forensic Med 2005; 12:271.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/47\" class=\"nounderline abstract_t\">Otedo AE. Halothane induced hepatitis: case report. East Afr Med J 2004; 81:538.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/48\" class=\"nounderline abstract_t\">Eghtesadi-Araghi P, Sohrabpour A, Vahedi H, Saberi-Firoozi M. Halothane hepatitis in Iran: a review of 59 cases. World J Gastroenterol 2008; 14:5322.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/49\" class=\"nounderline abstract_t\">Soleimanpour H, Safari S, Rahmani F, et al. The role of inhalational anesthetic drugs in patients with hepatic dysfunction: a review article. Anesth Pain Med 2015; 5:e23409.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/50\" class=\"nounderline abstract_t\">Brown BR Jr, Gandolfi AJ. Adverse effects of volatile anaesthetics. Br J Anaesth 1987; 59:14.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/51\" class=\"nounderline abstract_t\">Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6:755.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/52\" class=\"nounderline abstract_t\">Lo SK, Wendon J, Mieli-Vergani G, Williams R. Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation. Eur J Gastroenterol Hepatol 1998; 10:635.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/53\" class=\"nounderline abstract_t\">Kharasch ED. Adverse drug reactions with halogenated anesthetics. Clin Pharmacol Ther 2008; 84:158.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/54\" class=\"nounderline abstract_t\">Bond GR. Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report and speculation on mechanistic similarity to halothane induced hepatitis. J Toxicol Clin Toxicol 1996; 34:461.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/55\" class=\"nounderline abstract_t\">Kenna JG. The molecular basis of halothane-induced hepatitis. Biochem Soc Trans 1991; 19:191.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/56\" class=\"nounderline abstract_t\">Trowell J, Peto R, Smith AC. Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium. Lancet 1975; 1:821.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/57\" class=\"nounderline abstract_t\">Wright R, Eade OE, Chisholm M, et al. Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet 1975; 1:817.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/58\" class=\"nounderline abstract_t\">Safari S, Motavaf M, Seyed Siamdoust SA, Alavian SM. Hepatotoxicity of halogenated inhalational anesthetics. Iran Red Crescent Med J 2014; 16:e20153.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/59\" class=\"nounderline abstract_t\">Fee JP, Thompson GH. Comparative tolerability profiles of the inhaled anaesthetics. Drug Saf 1997; 16:157.</a></li><li class=\"breakAll\">Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver, Appleton-Century-Crofts, New York 1978.</li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/61\" class=\"nounderline abstract_t\">Mushin WW, Rosen M, Jones EV. Post-halothane jaundice in relation to previous administration of halothane. Br Med J 1971; 3:18.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/62\" class=\"nounderline abstract_t\">Gut J. Molecular basis of halothane hepatitis. Arch Toxicol Suppl 1998; 20:3.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/63\" class=\"nounderline abstract_t\">Inman WH, Mushin WW. Jaundice after repeated exposure to halothane: an analysis of Reports to the Committee on Safety of Medicines. Br Med J 1974; 1:5.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/64\" class=\"nounderline abstract_t\">Moult PJ, Sherlock S. Halothane-related hepatitis. A clinical study of twenty-six cases. Q J Med 1975; 44:99.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/65\" class=\"nounderline abstract_t\">Habibollahi P, Mahboobi N, Esmaeili S, et al. Halothane-induced hepatitis: A forgotten issue in developing countries: Halothane-induced hepatitis. Hepat Mon 2011; 11:3.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/66\" class=\"nounderline abstract_t\">Voigt MD, Workman B, Lombard C, Kirsch RE. Halothane hepatitis in a South African population--frequency and the influence of gender and ethnicity. S Afr Med J 1997; 87:882.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/67\" class=\"nounderline abstract_t\">Cousins MJ, Plummer JL, Hall PD. Risk factors for halothane hepatitis. Aust N Z J Surg 1989; 59:5.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/68\" class=\"nounderline abstract_t\">Inman WH, Mushin WW. Jaundice after repeated exposure to halothane: a further analysis of reports to the Committee on Safety of Medicines. Br Med J 1978; 2:1455.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/69\" class=\"nounderline abstract_t\">Dugan CM, MacDonald AE, Roth RA, Ganey PE. A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther 2010; 333:364.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/70\" class=\"nounderline abstract_t\">Fleifel WAN. Effects of halothane anesthesia on patients with abnormal liver function tests. J Basrah Res ((Sciences)) 2011; 4:84.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/71\" class=\"nounderline abstract_t\">Neuberger JM. Halothane and hepatitis. Incidence, predisposing factors and exposure guidelines. Drug Saf 1990; 5:28.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/72\" class=\"nounderline abstract_t\">Holt C, Csete M, Martin P. Hepatotoxicity of anesthetics and other central nervous system drugs. Gastroenterol Clin North Am 1995; 24:853.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/73\" class=\"nounderline abstract_t\">Kenna JG, Satoh H, Christ DD, Pohl LR. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988; 245:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/74\" class=\"nounderline abstract_t\">Beaune P, Pessayre D, Dansette P, et al. Autoantibodies against cytochromes P450: role in human diseases. Adv Pharmacol 1994; 30:199.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/75\" class=\"nounderline abstract_t\">Kenna JG, Neuberger JM. Immunopathogenesis and treatment of halothane hepatitis. Clin Immunother 1995; 3:108.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/76\" class=\"nounderline abstract_t\">Spracklin DK, Thummel KE, Kharasch ED. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos 1996; 24:976.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/77\" class=\"nounderline abstract_t\">Sipes IG, Gandolfi AJ, Pohl LR, et al. Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane. J Pharmacol Exp Ther 1980; 214:716.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/78\" class=\"nounderline abstract_t\">Kharasch ED, Hankins DC, Fenstamaker K, Cox K. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur J Clin Pharmacol 2000; 55:853.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/79\" class=\"nounderline abstract_t\">Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997; 84:173.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/80\" class=\"nounderline abstract_t\">Masubuchi Y, Horie T. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit Rev Toxicol 2007; 37:389.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/81\" class=\"nounderline abstract_t\">Minoda Y, Kharasch ED. Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology 2001; 95:509.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/82\" class=\"nounderline abstract_t\">Carpenter RL, Eger EI 2nd, Johnson BH, et al. The extent of metabolism of inhaled anesthetics in humans. Anesthesiology 1986; 65:201.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/83\" class=\"nounderline abstract_t\">Rehder K, Forbes J, Alter H, et al. Halothane biotransformation in man: a quantitative study. Anesthesiology 1967; 28:711.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/84\" class=\"nounderline abstract_t\">Kenna JG, Jones RM. The organ toxicity of inhaled anesthetics. Anesth Analg 1995; 81:S51.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/85\" class=\"nounderline abstract_t\">Spracklin DK, Hankins DC, Fisher JM, et al. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther 1997; 281:400.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/86\" class=\"nounderline abstract_t\">de Groot H, Noll T. Halothane hepatotoxicity: relation between metabolic activation, hypoxia, covalent binding, lipid peroxidation and liver cell damage. Hepatology 1983; 3:601.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/87\" class=\"nounderline abstract_t\">Reichle FM, Conzen PF. Halogenated inhalational anaesthetics. Best Pract Res Clin Anaesthesiol 2003; 17:29.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/88\" class=\"nounderline abstract_t\">Gelman S, Dillard E, Bradley EL Jr. Hepatic circulation during surgical stress and anesthesia with halothane, isoflurane, or fentanyl. Anesth Analg 1987; 66:936.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/89\" class=\"nounderline abstract_t\">Gelman S. General anesthesia and hepatic circulation. Can J Physiol Pharmacol 1987; 65:1762.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/90\" class=\"nounderline abstract_t\">Cousins MJ, Sharp JH, Gourlay GK, et al. Hepatotoxicity and halothane metabolism in an animal model with application for human toxicity. Anaesth Intensive Care 1979; 7:9.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/91\" class=\"nounderline abstract_t\">Cowan RE, Jackson BT, Grainger SL, Thompson RP. Effects of anesthetic agents and abdominal surgery on liver blood flow. Hepatology 1991; 14:1161.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/92\" class=\"nounderline abstract_t\">Jenner MA, Plummer JL, Cousins MJ. Halothane reductive metabolism in an adult surgical population. Anaesth Intensive Care 1990; 18:395.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/93\" class=\"nounderline abstract_t\">Manno M, Ferrara R, Cazzaro S, et al. Suicidal inactivation of human cytochrome P-450 by carbon tetrachloride and halothane in vitro. Pharmacol Toxicol 1992; 70:13.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/94\" class=\"nounderline abstract_t\">Baker MT, Vasquez MT, Chiang CK. Evidence for the stability and cytochrome P450 specificity of the phenobarbital-induced reductive halothane-cytochrome P450 complex formed in rat hepatic microsomes. Biochem Pharmacol 1991; 41:1691.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/95\" class=\"nounderline abstract_t\">Awad JA, Horn JL, Roberts LJ 2nd, Franks JJ. Demonstration of halothane-induced hepatic lipid peroxidation in rats by quantification of F2-isoprostanes. Anesthesiology 1996; 84:910.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/96\" class=\"nounderline abstract_t\">Plummer JL, Beckwith AL, Bastin FN, et al. Free radical formation in vivo and hepatotoxicity due to anesthesia with halothane. Anesthesiology 1982; 57:160.</a></li><li class=\"breakAll\">Zimmerman HJ. Drug-induced liver disease. In: Schiff's diseases of the liver, Schiff E, Sorrell M, Maddrey WC (Eds), Lippincott-Raven, Philadelphia 1999. p.973.</li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/98\" class=\"nounderline abstract_t\">Krieter PA, van Dyke RA. Cytochrome P-450 and halothane metabolism. Decrease in rat liver microsomal P-450 in vitro. Chem Biol Interact 1983; 44:219.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/99\" class=\"nounderline abstract_t\">Bourdi M, Amouzadeh HR, Rushmore TH, et al. Halothane-induced liver injury in outbred guinea pigs: role of trifluoroacetylated protein adducts in animal susceptibility. Chem Res Toxicol 2001; 14:362.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/100\" class=\"nounderline abstract_t\">Royston D. Free radicals. Formation, function and potential relevance in anaesthesia. Anaesthesia 1988; 43:315.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/101\" class=\"nounderline abstract_t\">Pohl LR, Satoh H, Christ DD, Kenna JG. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 1988; 28:367.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/102\" class=\"nounderline abstract_t\">Pessayre D, Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol 1988; 2:385.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/103\" class=\"nounderline abstract_t\">Neuberger J, Williams R. Halothane anaesthesia and liver damage. Br Med J (Clin Res Ed) 1984; 289:1136.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/104\" class=\"nounderline abstract_t\">Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996; 347:1367.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/105\" class=\"nounderline abstract_t\">Satoh H, Fukuda Y, Anderson DK, et al. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther 1985; 233:857.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/106\" class=\"nounderline abstract_t\">Kenna JG, Martin JL, Satoh H, Pohl LR. Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab Dispos 1990; 18:788.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/107\" class=\"nounderline abstract_t\">Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11:969.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/108\" class=\"nounderline abstract_t\">Kenna JG, Neuberger J, Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 1988; 8:1635.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/109\" class=\"nounderline abstract_t\">Trudell JR, Ardies CM, Anderson WR. Antibodies raised against trifluoroacetyl-protein adducts bind to N-trifluoroacetyl-phosphatidylethanolamine in hexagonal phase phospholipid micelles. J Pharmacol Exp Ther 1991; 257:657.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/110\" class=\"nounderline abstract_t\">Beaune PH, Lecoeur S. Immunotoxicology of the liver: adverse reactions to drugs. J Hepatol 1997; 26 Suppl 2:37.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/111\" class=\"nounderline abstract_t\">Dansette PM, Bonierbale E, Minoletti C, et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998; 23:443.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/112\" class=\"nounderline abstract_t\">Anderson JS, Rose NR, Martin JL, et al. Desflurane hepatitis associated with hapten and autoantigen-specific IgG4 antibodies. Anesth Analg 2007; 104:1452.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/113\" class=\"nounderline abstract_t\">Njoku DB. Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. Int J Mol Sci 2014; 15:6990.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/114\" class=\"nounderline abstract_t\">Eger EI 2nd, Koblin DD, Bowland T, et al. Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 1997; 84:160.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/115\" class=\"nounderline abstract_t\">Vergani D, Mieli-Vergani G, Alberti A, et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 1980; 303:66.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/116\" class=\"nounderline abstract_t\">Mieli-Vergani G, Vergani D, Tredger JM, et al. Lymphocyte cytotoxicity to halothane altered hepatocytes in patients with severe hepatic necrosis following halothane anaesthesia. J Clin Lab Immunol 1980; 4:49.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/117\" class=\"nounderline abstract_t\">Kenna JG, Scatchard K, Van Pelt FN, et al. Antibodies to halothane-induced liver antigens in sera from patients with halothane hepatitis: Evidence for a conformation-dependent antigen. Br J Clin Pharmacol 1992; 34:154.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/118\" class=\"nounderline abstract_t\">Chen M, Gandolfi J. Characterization of the humoral immune response and hepatotoxicity after multiple halothane exposures in guinea pigs. Drug Metab Rev 1997; 29:103.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/119\" class=\"nounderline abstract_t\">Pohl LR, Kenna JG, Satoh H, et al. Neoantigens associated with halothane hepatitis. Drug Metab Rev 1989; 20:203.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/120\" class=\"nounderline abstract_t\">Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996; 50:573.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/121\" class=\"nounderline abstract_t\">Satoh H, Gillette JR, Davies HW, et al. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol Pharmacol 1985; 28:468.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/122\" class=\"nounderline abstract_t\">Hoft RH, Bunker JP, Goodman HI, Gregory PB. Halothane hepatitis in three pairs of closely related women. N Engl J Med 1981; 304:1023.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/123\" class=\"nounderline abstract_t\">Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996; 9:1159.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/124\" class=\"nounderline abstract_t\">Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 1993; 58:133.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/125\" class=\"nounderline abstract_t\">Gut J, Christen U, Huwyler J, et al. Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. Eur J Biochem 1992; 210:569.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/126\" class=\"nounderline abstract_t\">Christen U, Jen&ouml; P, Gut J. Halothane metabolism: the dihydrolipoamide acetyltransferase subunit of the pyruvate dehydrogenase complex molecularly mimics trifluoroacetyl-protein adducts. Biochemistry 1993; 32:1492.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/127\" class=\"nounderline abstract_t\">Heijink E, De Matteis F, Gibbs AH, et al. Metabolic activation of halothane to neoantigens in C57Bl/10 mice: immunochemical studies. Eur J Pharmacol 1993; 248:15.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/128\" class=\"nounderline abstract_t\">Christen U, B&uuml;rgin M, Gut J. Halothane metabolism: Kupffer cells carry and partially process trifluoroacetylated protein adducts. Biochem Biophys Res Commun 1991; 175:256.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/129\" class=\"nounderline abstract_t\">Huwyler J, Gut J. Exposure to the chlorofluorocarbon substitute 2,2-dichloro-1,1,1- trifluoroethane and the anesthetic agent halothane is associated with transient protein adduct formation in the heart. Biochem Biophys Res Commun 1992; 184:1344.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/130\" class=\"nounderline abstract_t\">Hastings KL, Thomas C, Hubbard AK, Gandolfi AJ. Screening for antibodies associated with halothane hepatitis. Br J Anaesth 1991; 67:722.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/131\" class=\"nounderline abstract_t\">Huwyler J, Aeschlimann D, Christen U, Gut J. The kidney as a novel target tissue for protein adduct formation associated with metabolism of halothane and the candidate chlorofluorocarbon replacement 2,2-dichloro-1,1,1-trifluoroethane. Eur J Biochem 1992; 207:229.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/132\" class=\"nounderline abstract_t\">Kenna JG, Martin JL, Pohl LR. The topography of trifluoroacetylated protein antigens in liver microsomal fractions from halothane treated rats. Biochem Pharmacol 1992; 44:621.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/133\" class=\"nounderline abstract_t\">Proctor WR, Chakraborty M, Chea LS, et al. Eosinophils mediate the pathogenesis of halothane-induced liver injury in mice. Hepatology 2013; 57:2026.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/134\" class=\"nounderline abstract_t\">Proctor WR, Chakraborty M, Fullerton AM, et al. Thymic stromal lymphopoietin and interleukin-4 mediate the pathogenesis of halothane-induced liver injury in mice. Hepatology 2014; 60:1741.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/135\" class=\"nounderline abstract_t\">Endo S, Yano A, Fukami T, et al. Involvement of miRNAs in the early phase of halothane-induced liver injury. Toxicology 2014; 319:75.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/136\" class=\"nounderline abstract_t\">Farrell G, Prendergast D, Murray M. Halothane hepatitis. Detection of a constitutional susceptibility factor. N Engl J Med 1985; 313:1310.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/137\" class=\"nounderline abstract_t\">You Q, Cheng L, Reilly TP, et al. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006; 44:1421.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/138\" class=\"nounderline abstract_t\">Otsuka S, Yamamoto M, Kasuya S, et al. HLA antigens in patients with unexplained hepatitis following halothane anesthesia. Acta Anaesthesiol Scand 1985; 29:497.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/139\" class=\"nounderline abstract_t\">BLACKBURN WR, NGAI SH, LINDENBAUM J. MORPHOLOGIC CHANGES IN HEPATIC NECROSIS FOLLOWING HALOTHANE ANESTHESIA IN MAN. Anesthesiology 1964; 25:270.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/140\" class=\"nounderline abstract_t\">Moore DH, Benson GD. Prolonged halothane hepatitis. Prompt resolution of severe lesion with corticosteroid therapy. Dig Dis Sci 1986; 31:1269.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/141\" class=\"nounderline abstract_t\">Windsor JA, Wynne-Jones G. Halothane hepatitis and prompt resolution with methionine therapy: case report. N Z Med J 1988; 101:502.</a></li><li><a href=\"https://www.uptodate.com/contents/halothane-hepatitis/abstract/142\" class=\"nounderline abstract_t\">Elliott RH, Strunin L. Hepatotoxicity of volatile anaesthetics. Br J Anaesth 1993; 70:339.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3633 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL FEATURES</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Halothane hepatotoxicity</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Halothane hepatitis</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">MECHANISM OF HEPATOTOXICITY</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Halothane hepatotoxicity</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Halothane hepatitis</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">DIAGNOSIS</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">TREATMENT</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">PREVENTION</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-liver-failure-in-adults-management-and-prognosis\" class=\"medical medical_review\">Acute liver failure in adults: Management and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">Drug-induced liver injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatotoxicity-due-to-herbal-medications-and-dietary-supplements\" class=\"medical medical_review\">Hepatotoxicity due to herbal medications and dietary supplements</a></li></ul></div></div>","javascript":null}